Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oxford Nanopore Technologies plc is a UK-based biotechnology company specializing in nanopore-based sequencing technology for the real-time, label-free analysis of single molecules of DNA and RNA. Founded in 2005 as a spin-out from the University of Oxford, it develops portable and high-throughput devices like the MinION (a palm-sized USB sequencer), GridION (desktop system for multiple flow cells), and PromethION (for ultra-high output), alongside automated sample preparation tools such as VolTRAX. The company's business model provides sequencers often at no upfront cost, generating revenue primarily from consumables, services, and leasing in segments like sale of goods and technical support. Its platforms enable applications in infectious diseases, human genetics, cancer research, microbiome analysis, epigenetics, outbreak surveillance, and crop science, serving life sciences, healthcare, and in vitro diagnostics. Headquartered at Oxford Science Park with around 1,315 employees, Oxford Nanopore Technologies plc plays a pivotal role in democratizing genomic analysis by making it accessible, scalable, and deployable anywhere.
£1.20
£0.03 (-2.67%)
EOD Jul 3, 2026
The business is unprofitable at the operating level (-69.36% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 22.2% YoY with margins expanding 13.8pp.
ROIC dropped from -18.26% to -21.58%, capital efficiency is deteriorating. Negative free cash flow of -£116M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£224M
▲ +22.2% YoY
Net Income (TTM)
-£145M
▲ +0.7% YoY
Op. Margin
-69.36%
▲ +13.8pp YoY
ROIC
-21.58%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£116M
▲ +26.6% YoY
Op. Cash Flow (TTM)
-£113M
▲ +22.0% YoY
Net Debt
-£214M
Net Cash Position
Cash & Equiv.
£255M
3Y CAGR: +4.1%
Continue Research
Oxford Nanopore Technologies (ONT.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oxford Nanopore Technologies scores 18/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oxford Nanopore Technologies scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -69.4% operating margin and a -21.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ONT.XLON's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.